Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin Effects on ADL in Parkinson's Disease Psychosis
NCT04292223Phase 4Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Feb 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pimavanserin in Parkinson's disease (PD), sponsored by Acadia Pharmaceuticals. Primary endpoint: Modified Functional Status Questionnaire Total Score at 16 weeks. Started Feb 2020; status: completed.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04292223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04292223.